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Delayed Sleep-Wake Phase Disorder (DSWPD) is characterised by sleep initiation insom-
nia when attempting sleep at conventional times and difficulty waking at the required time
for daytime commitments. Although there are published therapeutic guidelines for the
administration of melatonin for DSWPD, to our knowledge, randomised controlled trials are
lacking. This trial tested the efficacy of 0.5 mg melatonin, combined with behavioural sleep-
wake scheduling, for improving sleep initiation in clinically diagnosed DSWPD patients with
a delayed endogenous melatonin rhythm relative to patient-desired (or -required) bedtime
(DBT).
Methods
This randomised, placebo-controlled, double-blind clinical trial was conducted in an Austra-
lian outpatient DSWPD population. Following 1-wk baseline, clinically diagnosed DSWPD
patients with delayed melatonin rhythm relative to DBT (salivary dim light melatonin onset
[DLMO] after or within 30 min before DBT) were randomised to 4-wk treatment with 0.5 mg
fast-release melatonin or placebo 1 h before DBT for at least 5 consecutive nights per week.







Citation: Sletten TL, Magee M, Murray JM, Gordon
CJ, Lovato N, Kennaway DJ, et al. (2018) Efficacy
of melatonin with behavioural sleep-wake
scheduling for delayed sleep-wake phase disorder:
A double-blind, randomised clinical trial. PLoS Med
15(6): e1002587. https://doi.org/10.1371/journal.
pmed.1002587
Academic Editor: David Peiris, The George
Institute for Global Health, UNSW Sydney,
AUSTRALIA
Received: September 22, 2017
Accepted: May 15, 2018
Published: June 18, 2018
Copyright: © 2018 Sletten et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information
files.
Funding: The study was funded by a project grant
from the National Health and Medical Research
Council (NHMRC; 1031513) to SMWR, SWL, RRG,
LCL, DJK and research support from the NHMRC
Australasian Sleep Trials Network. Financial
support for recruitment advertising was provided
All patients received behavioural sleep-wake scheduling, consisting of bedtime scheduled
at DBT. The primary outcome was actigraphic sleep onset time. Secondary outcomes were
sleep efficiency in the first third of time in bed (SE T1) on treatment nights, subjective sleep-
related daytime impairment (Patient Reported Outcomes Measurement Information System
[PROMIS]), PROMIS sleep disturbance, measures of daytime sleepiness, clinician-rated
change in illness severity, and DLMO time.
Findings
Between September 13, 2012 and September 1, 2014, 307 participants were registered;
116 were randomised to treatment (intention-to-treat n = 116; n = 62 males; mean age, 29.0
y). Relative to baseline and compared to placebo, sleep onset occurred 34 min earlier (95%
confidence interval [CI] −60 to −8) in the melatonin group. SE T1 increased; PROMIS sleep-
related impairment, PROMIS sleep disturbance, insomnia severity, and functional disability
decreased; and a greater proportion of patients showed more than minimal clinician-rated
improvement following melatonin treatment (52.8%) compared to placebo (24.0%) (P <
0.05). The groups did not differ in the number of nights treatment was taken per protocol.
Post-treatment DLMO assessed in a subset of patients (n = 43) was not significantly differ-
ent between groups. Adverse events included light-headedness, daytime sleepiness, and
decreased libido, although rates were similar between treatment groups. The clinical bene-
fits or safety of melatonin with long-term treatment were not assessed, and it remains
unknown whether the same treatment regime would benefit patients experiencing DSWPD
sleep symptomology without a delay in the endogenous melatonin rhythm.
Conclusions
In this study, melatonin treatment 1 h prior to DBT combined with behavioural sleep-wake
scheduling was efficacious for improving objective and subjective measures of sleep distur-
bances and sleep-related impairments in DSWPD patients with delayed circadian phase rel-
ative to DBT. Improvements were achieved largely through the sleep-promoting effects of
melatonin, combined with behavioural sleep-wake scheduling.
Trial registration
This trial was registered with the Australian New Zealand Clinical Trials Registry,
ACTRN12612000425897.
Author summary
Why was this study done?
• Circadian disruption—and Delayed Sleep-Wake Phase Disorder (DSWPD) specifically
—is associated with significant morbidity, including depression, poor academic and
work performance, and adverse social and economic outcomes.
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• Previous studies examining treatments for DSWPD have typically diagnosed the disor-
der based on sleep symptomology, not circadian timing, which may result in misdiagno-
sis of sleep initiation insomnia as DSWPD and thus inappropriate treatment.
• Although exogenous melatonin has been widely advocated as a treatment for DSWPD,
the therapeutic potential of the sleep-promoting effects of melatonin have not been eval-
uated rigorously in a randomised controlled trial in well-characterised DSWPD patients.
What did the researchers do and find?
• DSWPD patients (n = 116) with a delayed melatonin rhythm relative to patient desired
bedtime (DBT) completed a 4-wk trial of melatonin (0.5 mg) or placebo administered 1
h prior to DBT, combined with a behavioural sleep-wake intervention consisting of
attempting sleep at the patient DBT for at least 5 nights per week.
• Relative to baseline, sleep onset time was 34 min earlier, sleep efficiency during the first
tertile of sleep (SE T1) was greater, and sleep-related functional impairment was lower
in the melatonin group compared to placebo.
• Sleep disturbance, insomnia severity, and functional disability decreased, and a greater
proportion of patients showed clinician-rated improvement following melatonin treat-
ment (52.8%) compared to placebo (24.0%).
• The observed improvements in sleep were clinically significant according to clinical
practice guidelines for the treatment of circadian rhythm sleep disorders and compared
to other established therapeutic approaches.
What do the findings mean?
• Melatonin treatment, when combined with behavioural sleep-wake scheduling, is effica-
cious for improving sleep disturbances and sleep-related impairments in DSWPD
patients and potentially in other patients who show abnormal circadian timing relative
to sleep.
• Current melatonin treatment protocols for DSWPD vary in patient diagnostic criteria;
vary in the dose, formulation, and timing of melatonin; and may result in low compli-
ance due to the requirement for strict adherence every day.
• These findings contribute to the evidence base to improve the diagnosis of DSWPD and
the development of a standardised treatment protocol.
Introduction
Delayed Sleep-Wake Phase Disorder (DSWPD) is characterised by sleep initiation insomnia
when attempting sleep at conventional times and difficulty waking at the required time for
daytime commitments such as work or school [1,2]. DSWPD is often associated with chronic
sleep restriction [3] and adverse academic, occupational, financial, mental health, and social
outcomes [4–6].
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The intrinsic basis for DSWPD manifests in a delay in endogenous circadian timing [2,3,7].
Current diagnostic criteria [1], however, do not specifically include circadian timing, which
may result in misdiagnosis of sleep initiation insomnia as DSWPD [8]. Individuals may also
present with delayed sleep-wake behaviour due to differences in homeostatic sleep drive not
related to circadian timing and thus still show differences in sleep onset timing relative to
those with healthy sleep [9]. Previous trials examining treatments for DSWPD have typically
diagnosed the disorder based on sleep symptomology, not circadian timing [10–14].
Although exogenous melatonin has been suggested for clinical treatment of DSWPD [15],
standardised evidence-based therapeutic guidelines are lacking. In addition to the circadian
phase-shifting effects of melatonin, the hormone has direct, sleep-promoting effects [16]. The
therapeutic potential of these sleep-promoting effects has not been evaluated rigorously in a
randomised controlled trial in DSWPD patients. Such a treatment approach would be benefi-
cial for this patient group, which may use melatonin to facilitate sleep at an earlier time only as
required, for example, on nights before school or work days.
The aim of this study was to test—in a randomised, double-blind, parallel-groups, placebo-
controlled outpatient trial—the efficacy of melatonin (0.5 mg) for DSWPD patients with con-
firmed delay of the endogenous melatonin rhythm relative to desired or required bedtime
using a pragmatic, clinically relevant protocol that included behavioural sleep-wake scheduling
(sleeping at desired or required bedtime) for all participants. Specifically, we tested the hypoth-
esis that, compared to placebo, administration of melatonin 1 h prior to the patient’s predeter-
mined desired (or required) bedtime for 4 wk would advance the time of sleep onset. As
secondary outcomes, we hypothesised that compared to placebo, melatonin treatment would
result in (1) increased sleep efficiency in the first third of the sleep episode (SE T1), (2) reduced
subjective sleep-related daytime impairments, (3) reduced self-reported sleep disturbances and
daytime sleepiness, (4) a greater proportion of change in the clinician-rated change in severity
of illness, and (5) an advance in the timing of the endogenous circadian pacemaker.
Methods
Study design
The Delayed Sleep on Melatonin (DelSoM) study was a multicentre, double-blind randomised
controlled trial conducted at 3 study sites in Australia: Monash University in Melbourne,
Woolcock Institute of Medical Research in Sydney, and Flinders University in Adelaide.
Data were collected between September 2012 and September 2014. The study protocol was
approved by the Monash University Human Research Ethics Committee, the University of
Sydney Human Research Ethics Committee, University of Adelaide Human Research Ethics
Committee, and Southern Adelaide Clinical Human Research Ethics Committee. The trial was
registered with the Australian New Zealand Clinical Trials Registry
(ACTRN12612000425897).
Participants and recruitment
Participants were males and females aged between 16 and 65 y with body mass index between
18 and 35 kg/m2 who had daytime commitments on5 d per week. They had no reported
history of psychiatric disorders in the past 12 mo (other than depression), reported no illicit
drug use for at least 12 mo, were nonsmokers, and consumed low habitual amounts of caffeine
(<300 mg/d) and alcohol (<14 units/wk). Participants were not working regular night shifts
and had not travelled across more than 2 time zones in the previous 2 mo. Participants
were recruited via radio, newspaper, television and poster advertisements, and via clinician
referrals. Potential participants were identified as displaying symptoms of DSWPD via online
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questionnaire and were interviewed via telephone before attending a screening visit. Following
consent, patients were assessed by a sleep physician who confirmed they met International
Classification of Sleep Disorders-2 diagnostic criteria for DSWPD [17] based on clinical inter-
view. Participants provided written informed consent prior to study commencement.
Baseline questionnaire, sleep-wake, and circadian phase assessments
DSWPD diagnostic criteria were assessed via clinical interview, and because 7-d collection
of actigraphy and sleep diaries were used as assessment outcomes at baseline, they were not
used as part of diagnosis. After the clinical interview, a sleep physician completed the Clinical
Global Impression-Severity (CGI-S) scale [18] as a measure of global functioning prior to
treatment. Participants completed pretreatment surveys, including the Pittsburgh Sleep Qual-
ity Index (PSQI) [19] for subjective sleep quality, Epworth Sleepiness Scale (ESS) to assess day-
time sleepiness [20], Morningness-Eveningness Questionnaire to assess diurnal preference
[21], Insomnia Severity Index (ISI) [22], Beck Depression Inventory version 2 (BDI-II) as a
measure of current experience of depressive symptoms [23], and Beck Anxiety Inventory [24].
The Sheehan Disability Scale (SDS) was completed to assess functional impairments in 3 inter-
related domains: work/school, social life, and family life, in addition to the rate of absenteeism
and presenteeism [25].
For 7 d, participants were monitored during their habitual sleep-wake schedule and regular
daytime commitments via sleep diaries and wrist actigraphy (Actiwatch-L, Actiwatch-2, or
Actiwatch Spectrum; Philips Respironics, Bend, OR). Participants also documented their daily
schedules to confirm daytime commitments on at least 5 consecutive days per week. On the
last morning, 1 to 4 h after waking, participants completed the Patient Reported Outcomes
Measurement Information System (PROMIS) as measures of sleep disturbance and sleep-
related daytime impairments, including symptoms of sleepiness, irritability, and difficulty con-
centrating [26].
After the outpatient sleep-wake assessment, participants attended the laboratory for assess-
ment of circadian phase via salivary dim light melatonin onset (DLMO). Participants arrived 6
h before their self-reported habitual sleep onset time and remained awake in a light-proof,
sound-attenuated, temperature-controlled suite until at least 2 h after their habitual sleep onset
time. Ambient light was maintained at<10 lux (measured in the direction of gaze at standard
height of seated eye level, 137 cm from the floor), and saliva samples (approximately 2 mL)
were collected hourly. Participants remained seated with limited movement for 20 min before
each sample and were not permitted to consume food or beverages within 10 min of each sam-
ple. They were permitted to watch television (<10 lux), read, and engage in quiet activities
between samples. Samples were collected (Salivette, Sarstedt, Numbrecht, Germany) as previ-
ously described [27] and stored at −20 ˚C. After the final sample, participants were transported
home.
Saliva (200 μl) was assayed in triplicate for melatonin by radioimmunoassay within 1 wk of
collection, using procedures developed at the University of Adelaide [28] and reagents pro-
vided by Buhlmann Laboratories (Allschwil, Switzerland). Limit of detection of the assay was 1
pg/mL, the inter-assay coefficient of variations were 7.4% at 4.41 pg/mL and 10.7% at 48.14
pg/mL, and the intra-assay coefficient of variation was 9.9%. The time of DLMO for each par-
ticipant was calculated as the time that melatonin concentrations crossed and remained above
a threshold of 2.3 pg/mL (10 pM), calculated from linear interpolation between the samples
immediately before and after the threshold [27]. Participants were classified as having a
delayed circadian phase angle if DLMO occurred within 30 min before their reported desired
bedtime (DBT) or any time after DBT. DBT was derived from the response to the following
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question: ‘On the night before school or work, what time would you need to go to bed in order
to feel fully rested in the morning?’ It was considered that, for individuals with DLMO before
DBT, abnormal timing of the central circadian pacemaker was not likely to be the primary
cause of their sleep initiation complaints at DBT. Although these individuals present with simi-
lar difficulties in sleep initiation, the phenotype of circadian rhythm sleep disorder is not pres-
ent [8], and the optimal treatment regimens for each may not be the same. To account for
potential measurement error in DLMO and/or DBT, individuals with DLMO occurring up to
30 min before DBT were also classified as having circadian delay. In cases of actigraphy mal-
function or noncompliance (Actiwatch worn during <5 sleep episodes or not worn for the 2
nights prior to DLMO assessment), participants repeated the sleep-wake monitoring after the
DLMO assessment (n = 9).
Randomisation and treatment
Individuals with a confirmed delayed circadian phase angle were randomised to treatment
with placebo or 0.5 mg fast-release melatonin (Pure Encapsulations; Sudbury, MA). Partici-
pants were assigned to treatment arms using permuted blocks randomisation (n = 6) in a 1:1
ratio. An externally appointed biostatistician was responsible for randomisation procedures.
Administration of medication type was double-blinded. Blinding of medication conditions
was conducted by a pharmacist at Monash University. Medication was dispensed by a univer-
sity (Monash) or local (Woolcock, Flinders) pharmacist. Placebo capsules were lactose and cel-
lulose and were identical in size and appearance to the melatonin capsule.
Participants were provided with 28 medication capsules and instructed to take a capsule at
the same clock time each night 1 h before their fixed DBT and to attempt sleep at their DBT
each night prior to daytime commitments, as the behavioural sleep-wake scheduling compo-
nent of the protocol, for at least 5 consecutive nights of every 7 nights for 4 consecutive weeks.
To assess compliance with medication and inform analyses, participants self-reported the pre-
cise time of administration each night and returned unused capsules at study end. During the
treatment period, sleep-wake monitoring was continued with sleep diaries and wrist actigra-
phy. Participants continued to document their daily work schedules, and at the end of each
week, they completed the PROMIS. Participants were contacted by researchers via telephone
each week to promote compliance with the protocol and monitor potential adverse events.
The protocol for melatonin administration an hour before DBT rather than habitual bed-
time was developed by taking into consideration the available evidence of the phase resetting
and sleep-promoting effects of melatonin and what was deemed to be achievable in a clinical
setting based on our experience. First, we determined that melatonin would be administered
on nights in which the participant needed to advance their bedtime rather than requiring
adherence every night. We expected melatonin to be efficacious using this approach because
of the acute sleep-promoting effects of the hormone and also the immediate phase-shifting
effect. A single night of administration of a melatonin agonist can produce a phase advance in
humans [29,30], and the rhythm of light-induced c-Fos gene expression in the suprachiasmatic
nuclei is immediately shifted following melatonin administration in animal models [31]. The
dose of melatonin we used was selected based on previous work showing no difference in
improvements in sleep latency or sleep efficiency (SE) between 0.5 mg and 5 mg compared to
placebo in healthy volunteers in a controlled setting [32]. We also selected the minimal effec-
tive dose to avoid the potential for residual (next-morning) effects on neurocognitive function
and on the circadian pacemaker, which may occur if higher doses of melatonin remain in cir-
culation for a longer duration. We do note, however, that the phase-response curves reported
for 0.5 mg and 3 mg melatonin do not markedly differ [33]. Whether doses exceeding 3 mg of
Melatonin and sleep-wake scheduling for delayed sleep-wake phase disorder
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002587 June 18, 2018 6 / 24
melatonin alter the phase-resetting response is presently unclear. A standard fast-release prep-
aration of melatonin was administered to rapidly induce high circulating levels close to the
time of desired sleep onset but to avoid residual (circadian phase-shifting) effects towards the
end of the sleep episode. The metabolism and pharmacokinetics of such melatonin prepara-
tions have been well described [34,35]. In one study in which the dose-response effects of
melatonin were examined, for 0.5 mg of melatonin, the time taken to reach maximum concen-
tration was 30 min, and the elimination half-life was 42.6 + 12.6 min [36].
Post-treatment assessments
Within 7 d of treatment end, participants met a sleep physician for completion of post-treat-
ment CGI-S. Participants completed the Patients’ Global Impression of Change (PGI-C) Scale
[18] and repeated the PSQI, ESS, ISI, SDS, BDI-II, and BAI as post hoc secondary outcomes.
In a subset of participants at the Monash site (n = 49/104; n = 27 melatonin; and n = 22 pla-
cebo), a follow-up DLMO assessment was conducted 24 h after completing treatment. Post-
treatment DLMO assessments were conducted in the participants’ home. They remained
seated in a dimly lit room (<10 lux at participant eye level, vertical plane) and collected saliva
samples every hour from 5 h before until 2 h after their treatment bedtime. During the 7-h
saliva collection, participants were able to watch television, read, and engage in quiet activities
between samples. Research staff measured the at-home lighting to ensure dim conditions prior
to the first sample and remained present for the first sample. Home saliva sampling for DLMO
assessment under controlled conditions of light and sample timing correlate highly with labo-
ratory assessments [37]. Post-treatment DLMO assessments were only available at 1 site (Mon-
ash) due to researcher availability and participants opted-in to this aspect of the protocol.
Statistical analysis
The original study sample size was planned based on a meta-analysis of the efficacy of melato-
nin for DSWPD in adults, which reported a 0.70-h mean difference in sleep onset time
between melatonin and placebo [38]. The pooled results in the meta-analysis primarily based
on actigraphic data suggested that a sample size of n = 79 patients per group (158 in total)
would have 90% power at 0.05 significance level to show a 0.94 h (SD = 1.82) difference in
sleep onset time between groups. The sample size was not reached due to budgetary con-
straints and slower than anticipated patient recruitment.
Intention-to-treat analyses were conducted as per the Consolidated Standards of Reporting
Trials (S1 CONSORT Checklist). We defined the intention-to-treat population as all rando-
mised individuals for whom trial medication was dispensed (n = 116). Actigraphic and subjec-
tive sleep variables were calculated for all nights on which medication was taken because
DSWPD symptoms manifest when the patient attempts to sleep at their desired or required
bedtime (prior to school or work commitments the following day), and not when they sleep at
the biologically driven time. Therefore, the trial design required that the medication be taken
on nights prior to school or work commitments. In post hoc sensitivity analyses, we included
only patients who completed the trial, using only nights during which they took medication
within 30 min of the scheduled time and attempted sleep within 1 h of taking the medication
(n = 104; completed treatment). No missing value imputation or substitution was performed.
Sleep diary reports of bedtime, sleep offset time, sleep onset latency (SOL), and wake after
sleep onset (WASO) were used to calculate the subjective sleep variables of time in bed (TIB),
sleep onset time, total sleep time (TST), and SE (calculated between sleep onset and sleep
offset). Bed and wake times reported in sleep diaries were used to identify sleep episodes for
actigraphy analysis in Actiware 5 software (Philips Respironics, Bend, OR). For actigraphic
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analyses, discrepancies between sleep diaries and actigraphy of60 min required correction
to match objective actigraphy. If the reported subjective bedtime was60 min prior to a sus-
tained substantial reduction in activity and light levels, bedtime was adjusted to the time of
activity and light reduction. If reported wake time was60 min after a sustained substantial
increase in activity and light levels, wake time was adjusted to match the time of increased
activity and light. An independent researcher visually reviewed alignment between diary and
actigraphic bed and wake times, and discrepancies were resolved by discussion and agreement
between 2 researchers (JMM and MM) before unblinding. Actiware software sensitivity was
set to medium (40 activity counts) to determine each 1-min epoch as sleep or wake.
The following actigraphic variables were computed for main sleep episodes: TIB, sleep
onset time, sleep offset time, rise time, TST (sleep onset to wake time minus awakenings), SOL
(minutes taken to fall asleep), SE (proportion of TIB that was sleep), and WASO (minutes of
wakefulness after sleep onset). Sleep onset was established as the first epoch in a series of at
least 10 min in which no more than 1 epoch contained measured activity. Sleep episodes were
divided into tertiles (from actigraphic bedtime to rise time), and SE was calculated separately
for each tertile.
Demographic and clinical characteristics were compared between placebo and treatment
groups at baseline for intention-to-treat (n = 116) and completed treatment (n = 104) popula-
tions. Categorical baseline data were summarised as frequencies as percentages, and compari-
sons between treatment groups were conducted using the chi-squared statistic. Continuous or
interval data were reported as means with their standard deviations, and linear regression was
used for group comparisons. Classifications of CGI and PGI-C were determined post hoc
based on the distribution of responses.
To establish whether there were study group differences in changes in outcomes from base-
line to intervention period, linear mixed models were used allowing for a random intercept
and slope. Linear mixed models compared the 7-d baseline period average to the average of
treatment nights for sleep parameters (actigraphic and sleep diary: bedtime, sleep onset and
offset times, TIB, TST, SOL, SE, and WASO; actigraphic: rise time and SE tertiles 1, 2, and 3).
The linear models used restricted maximum likelihood estimation and variance component
structures for residuals, and random effects were modelled by considering the best-fitting
structure. Mean change in sleep parameters from baseline nights to treatment nights were
compared between treatment groups using an interaction term for group (melatonin versus
placebo) and treatment period (baseline versus treatment).
Ordinal linear regression models were used to establish group comparisons of ISI, PSQI,
ESS, and SDS absenteeism and presenteeism. Binary outcomes (PSQI, PGI-C, ESS) were ana-
lysed using logistic regression, while ordinal logistic regression was used for groupings of ISI
and DSPD severity (i.e., CGI-S). Because these data were collected at 2 time points (baseline,
end of treatment), robust cluster sandwich estimators were employed to account for repeated
measures. Analyses were conducted using Stata Statistical software release 14.1 (StataCorp
2015, College Station, TX). Statistical significance was defined as a P value less than 0.05.
Unless otherwise stated, data are presented as mean ± SD.
Results
Preliminary online screening was completed by 3,522 individuals, of whom 307 were enrolled
in the study, 187 attended the laboratory-based circadian phase assessment, and 116 were ran-
domised to treatment (Fig 1). Of the 186 who completed the circadian phase assessment, 62
(33.3%) did not have circadian misalignment between DLMO and DBT (defined as DLMO
<30 min before or any time after DBT) and were excluded from the trial. Comparison of
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sleep-wake and mood characteristics of patients with and without circadian misalignment
from this trial are presented elsewhere [8].
Patients were initially screened via online questionnaires followed by telephone assessment,
and DSWPD symptomology was confirmed by a sleep physician. Circadian phase assessment
identified individuals who had delayed DLMO relative to desired or required bedtime, and
these individuals were randomly assigned to treatment. The intention-to-treat population
Fig 1. Participant recruitment and study enrolment flow chart.
https://doi.org/10.1371/journal.pmed.1002587.g001
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included the 116 patients who were randomised. There were 104 patients in the completed
treatment analysis.
Demographic and clinical characteristics of participants in each treatment group are pre-
sented in Table 1. Participants in the placebo and melatonin treatment groups did not differ in
sex, age, body mass index, morningness-eveningness scores, clinician-derived DSWPD sever-
ity, baseline DLMO, DBT, phase angle between DLMO and DBT, or phase angle between
DLMO and actigraphic habitual bedtime (Table 1; P> 0.05).
On average, patients took capsules (melatonin or placebo) on 21.11 ± 3.18 nights during
the 4-wk treatment protocol, with an average of 5.30 ± 1.00 nights per 7-d period. Of the total
completed sample (n = 104), 66.3% took capsules for at least 5 consecutive nights per week on
at least 3 of the 4 wk. Notably, only 5.0% opted to take capsules for 7 nights per week on all
weeks. The total number of nights for which patients complied with the treatment protocol
(capsule taken and bedtime as instructed) did not differ between groups (536 versus 614 nights
Table 1. Baseline demographic and clinical characteristics and relationship between DLMO and sleep timing among patients randomised to treatment with placebo
or melatonin.
Intention-to-Treat Completed Treatment
Placebo Melatonin P Placebo Melatonin P
No. 58 58 50 54
Sex (no. [%]) 32 (55) M, 26 (45) F 30 (52) M, 28 (48) F 0.710 25 (50) M, 25 (50) F 28 (52) M, 26 (48) F 0.850
Age (y): Mean ± SD 28.29 ± 9.96 29.72 ± 9.33 0.426 28.88 ± 10.46 29.94 ± 9.63 0.591
Median (IQR) 25 (21–31) 27 (24–36) 0.170 25 (21–33) 27.5 (23–36) 0.329
Range 17–60 17–64 17–60 17–64
Body mass index (kg/m2): Mean ± SD 24.68 ± 4.17 25.50 ± 4.43 0.308 24.66 ± 4.34 25.49 ± 4.43 0.340
Morningness-eveningness questionnaire: Mean ± SD 23.41 ± 4.44 24.57 ± 4.92 0.187 23.90 ± 4.33 24.57 ± 5.09 0.468
Median (IQR) 22 (20–27) 24 (21–27) 0.291 22.5 (21–27) 24 (21–27) 0.766
Evening (0–22): no. (%) 31 (53.4) 25 (43.1) 0.265 25 (50.0) 25 (46.3) 0.706
Intermediate (23–43): no. (%) 27 (46.6) 33 (56.9) 25 (50.0) 29 (53.7)
Morning (>44): no. (%) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
DSWPD severity, clinician-rated: no. (%)b
Mild 21 (37) 19 (33) 0.890 18 (37) 18 (33) 0.782
Moderate 30 (53) 33 (57) 25 (51) 31 (57)
Severe 6 (11) 6 (10) 6 (12) 5 (9)
Baseline DLMO (hh:mm): Mean ± SD 22:53 ± 1:16 22:54 ± 1:27 0.948 22:46 ± 1:12 22:52 ± 1:27 0.675
DBT (hh:mm): Mean ± SD 22:32 ± 0:56 22:23 ± 1:01 0.419 22:27 ± 0:56 22:25 ± 0:59 0.900
DBT-DLMO (h)c: Mean ± SD −0.35 ± 0.87 −0.51 ± 1.07 0.371 −0.32 ± 0.85 −0.45 ± 1.06 0.480
Median (IQR) −0.25 (−0.83 to 0.35) −0.14 (−1.00 to 0.30) 0.677 −0.21 (−0.83 to 0.35) −0.07 (−0.97 to 0.32) 0.848
HBT (hh:mm)a: Mean ± SD 00:59 ± 1:27 01:11 ± 1:14 0.419 00:50 ± 1:20 01:08 ± 1:15 0.263
HBT-DLMO (h)a,c: Mean ± SD 2.12 ± 0.97 2.31 ± 1.21 0.358 2.11 ± 0.89 2.28 ± 1.21 0.406
Planned treatment time per protocol (hh:mm):
Mean ± SD
21:32 ± 0:56 21:23 ± 1:01 0.419 21:27 ± 0:56 21:25 ± 0:59 0.900
Median (IQR) provided for variables with skewed distribution.
aHBT and HBT-DLMO for intention-to-treat groups; placebo n = 55; melatonin n = 56. HBT and HBT-DLMO for completed treatment groups; placebo n = 47;
melatonin n = 52.
bDSWPD severity for intention-to-treat placebo n = 57; DSWPD severity for completed treatment placebo n = 49.
cP values based on a t test of phase angles of the differences between DLMO and DBT or DLMO and HBT.
Abbreviations: DBT, subjective desired bedtime; DLMO, dim light melatonin onset; DSWPD, Delayed Sleep-Wake Phase Disorder; HBT, actigraphic habitual bedtime;
IQR, interquartile range; SD, standard deviation.
https://doi.org/10.1371/journal.pmed.1002587.t001
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for melatonin and placebo groups, respectively; P> 0.05). The circadian timing of scheduled
treatment (timing of capsule relative to baseline DLMO) was not different between the groups
(−1.35 ± 0.87 h for melatonin and −1.51 ± 1.07 h for the placebo group; P> 0.05).
Earlier bedtime in the placebo condition was associated with longer SOL and lower SE,
which was improved with melatonin treatment (Table 2, Fig 2). Relative to baseline, com-
pared to placebo, the melatonin group had 18.2-min-shorter subjective (95% confidence
interval [CI] −30.78 to −5.59; P = 0.005) and 11.9-min-shorter actigraphic (95% CI −19.54
to −4.39; P = 0.002) SOL, 44-min-earlier subjective (95% CI −66 to −21; P< 0.001) and
34-min-earlier actigraphic (95% CI −60 to −8; P = 0.011) sleep onset time, 38-min-earlier
subjective sleep offset time (95% CI −63 to −13; P = 0.003), 3.0% higher SE for the entire
sleep episode (95% CI 1.02–4.99; P = 0.003), and 5.14% higher SE T1 (95% CI 2.52–7.76;
P< 0.001) (Table 2, Fig 2a).
We conducted post hoc analyses of all nights of the treatment period (28 d), including the
nights on which treatment was not taken (Table 3). The melatonin group compared to the pla-
cebo group had a 29-min-earlier actigraphic sleep onset time (95% CI −54 to −4; P = 0.023)
and 4.37% greater SE T1 (95% CI 1.91, 6.83; P = 0.001). An example of the treatment effect for
a participant administered melatonin is plotted in Fig 3.
Sensitivity analyses were undertaken including only those nights on which patients took
treatment and went to bed according to the study protocol. Compared to placebo, the melato-
nin group had earlier actigraphic sleep onset time (26 min; 95% CI −51 to −2; P = 0.038),
higher SE T1 (5.50%; 95% CI 2.41–8.58; P< 0.001), shorter subjective (18.4 min; 95% CI
−34.21 to −2.66; P = 0.022) and objective (15.7 min; 95% CI −24.41 to −6.89; P< 0.001) SOL,
earlier subjective sleep onset time (40 min; 95% CI −67 to −14; P = 0.004), earlier subjective
sleep offset time (42 min; 95% CI −74 to −9; P = 0.013), and higher actigraphic SE for the entire
sleep episode (3.27%; 95% CI 1.30–5.24, P = 0.001).
For PROMIS Sleep Disturbance, a treatment by time interaction effect was found (F4,408 =
3.83, P = 0.005), and a significant main effect of time (F4,408 = 4.01, P = 0.003) but no main
effect of treatment (P = 0.112). Post hoc analysis showed that PROMIS Sleep Disturbance
score was lower in the melatonin group at week 3 (P = 0.042) and week 4 (P = 0.016) compared
to placebo (Fig 2b upper). PROMIS Sleep Related Impairment showed a treatment by time
interaction effect (F4,408 = 4.29, P = 0.002), a main effect of time (F4,408 = 37.12, P< 0.0001),
but no main effect of treatment (P = 0.102). Melatonin treatment resulted in significantly
lower PROMIS score for sleep-related impairment at week 1 (P = 0.035), week 3 (P = 0.042),
and week 4 (P = 0.018; Fig 2b lower).
Prior to treatment, participants in the treatment groups were not different on ratings on the
ISI, PSQI, ESS, SDS, absenteeism, or presenteeism (Table 4). Compared to placebo, ISI and
PSQI were significantly improved with melatonin treatment. Following treatment, the melato-
nin group reported a lower ISI score (P = 0.035) and included more individuals reporting
absent insomnia symptoms on the ISI (P = 0.008). Mean PSQI score post treatment was lower
in the melatonin group compared to placebo (P = 0.037). Significant treatment by time inter-
actions were observed for ISI (P = 0.004), PSQI (P = 0.023), and SDS (P = 0.045) (Table 4),
with melatonin treatment associated with larger reductions in each score. Absenteeism and
presenteeism post treatment were not different between groups.
CGI Global Improvement ratings were significantly different between treatment groups
(P = 0.011), with 52.8% (n = 28) of the melatonin group classified as very much/much
improved compared to 24.0% (n = 12) of the placebo group (Table 5). CGI Efficacy Index was
lower following melatonin treatment compared to placebo (P = 0.045). The proportion of
patients in the CGI Severity categories did not change following treatment (Table 5). Post-
treatment PGI-C scores did not differ between groups.
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Table 2. Subjective and objective sleep parameters at baseline and during nights of treatment with trial medication.
Baseline All treatment nights Treatment versus baseline by group Difference between
groups’ change from
baseline to treatment
Placebo Melatonin Placebo Melatonin Placebo Melatonin β (95% CI) P
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Post-treatment DLMO could not be calculated for 6 of the subset of 49 participants; melato-
nin concentrations were above threshold (2.3 pg/ml) at the start of the collection phase in 4
participants (n = 3 melatonin, n = 1 placebo), with higher levels in 1 participant indicating
that melatonin treatment was taken on the night of assessment. Concentrations did not cross
threshold for 2 participants (n = 1 melatonin, n = 1 placebo). Following melatonin treatment
(n = 23), DLMO was advanced by 0.73 ± 1.21 h, compared to 0.24 ± 1.11 h following placebo
(n = 20) although this difference did not reach statistical significance (P> 0.05).
No deaths or serious adverse events were reported for either treatment group, and no par-
ticipants discontinued due to adverse events. Adverse event rates did not differ between the
treatment groups (Table 6). Adverse events did not occur in more than 5% of patients taking
melatonin. Unusual dreaming was reported by 7% of the placebo group compared to 2% of the
melatonin group.
In post hoc analysis, we assessed whether the degree of ‘social jetlag’ observed in our
patients was affected by our melatonin treatment protocol. Social jetlag has been described as
the discrepancy between sleep timing on work and free days, thought to reflect the discrepancy
between social and biological time [39]. We operationalised this definition in our protocol by
comparing sleep timing on nights when medication was taken compared to when medication
was not taken because this was thought to reflect work and free nights, respectively. Data were
included when at least 2 nonmedication nights were available for each participant (n = 83).
Table 2. (Continued)
Baseline All treatment nights Treatment versus baseline by group Difference between
groups’ change from
baseline to treatment
Placebo Melatonin Placebo Melatonin Placebo Melatonin β (95% CI) P
Diff (95% CI) P Diff (95%
CI)
P
Sleep onset time (hh:
mm): Mean ± SD







Sleep offset time (hh:
mm): Mean ± SD











<0.001 −0.28 (−0.69 to
0.13)
0.179




<0.001 0.13 (−0.30 to
0.55)
0.563








Median (IQR) 30 (15–60) 30 (15–50) 40 (20–90) 30 (15–55)




0.366 3.16 (−0.41 to
6.73)
0.083

















Median (IQR) 10 (0–30) 5 (0–30) 10 (0–30) 5 (0–30)
Median (IQR) presented for variables with skewed distribution.
aUnderlined variable indicates primary outcome.
bBolded results indicate statistically significant parameters.
Abbreviations: CI, confidence interval; IQR, interquartile range; SD, standard deviation; SE, sleep efficiency; SOL, sleep onset latency; TIB, time in bed; TST, total sleep
time; WASO, wake after sleep onset.
https://doi.org/10.1371/journal.pmed.1002587.t002
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Consistent with previous studies, sleep timing was defined by mid-sleep, calculated here as the
midpoint between actigraphic sleep onset and sleep offset time. Median social jetlag was not
different between the melatonin group (1.17 [0.70–1.75], median [IQR]) and the placebo
group (0.89 [0.58–1.62]) (P> 0.05).
Discussion
In a sample of DSWPD patients with confirmed circadian misalignment, compared to placebo,
0.5 mg melatonin taken 1 h prior to patient-DBT in a pragmatic treatment protocol resulted in
earlier timing of sleep onset, improved sleep quality, and reduced sleep-related impairments.
Melatonin treatment reduced patient-reported sleep disturbance, insomnia severity, and day-
time functional disability and was associated with larger clinician-rated improvements in
symptoms. This is the largest placebo-controlled trial to assess the clinical efficacy of melatonin
to improve sleep initiation and sleep quality in DSWPD. The trial has assessed the effects of
melatonin when sleep is attempted at the patient-DBT in DSWPD patients with confirmed
circadian misalignment, using patient-reported (PROMIS, PSQI, ISI, SDS, PGI-C), clinician-
assessed (CGI-Global Improvement and Efficacy), and objective (actigraphic sleep onset time,
SOL, SE) assessments of sleep quality and daytime function.
We instructed patients to attempt sleep at their DBT during treatment, which resulted in
the sleep episode starting, on average, 2 h earlier than habitual bedtime during baseline. The
earlier timing in bedtime resulted in longer SOL for those on placebo, as expected for individu-
als attempting to sleep earlier in their circadian cycle [40]. Treatment with melatonin reduced
the time taken to fall asleep to near baseline levels and resulted in a 34-min-earlier sleep onset
and 36-min-earlier self-reported sleep offset time compared to placebo, exceeding consensus
recommendations of critical clinical significance thresholds for improvements in these out-
comes in DSWPD (15 min in both cases) [15]. Actigraphically recorded SE during the first ter-
tile of sleep and overall SE were also improved with melatonin treatment.
Fig 2. Change in actigraphic sleep parameters and subjective sleep quality and sleep-related impairment under treatment with melatonin and
placebo. (A) Predicted change (mean ± 95% CIs) from baseline to treatment phase in actigraphic sleep parameters for individuals during treatment
with placebo (open) and 0.5 mg melatonin (closed) (intention-to-treat analyses). Predicted values are derived from regression analyses to account for
intra- and inter-individual variability. P< 0.05. (B) Subjective measures of PROMIS Sleep Disturbance (upper) and PROMIS Sleep Related
Impairment (lower) (n = 116) at baseline and weeks 1–4 treatment with placebo (open symbols) and melatonin (closed symbols). Data are mean ± SE.
P< 0.05 for post hoc between groups t test; #P< 0.05 for treatment group x time. CI, confidence interval; PROMIS, Patient Reported Outcomes
Measurement Information System; SE, standard error.
https://doi.org/10.1371/journal.pmed.1002587.g002
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Melatonin treatment produced considerable improvements in subjective sleep complaints.
Patients taking melatonin reported improved sleep quality and reduced severity of insomnia
symptoms. A higher proportion of those taking melatonin also reported an absence of insom-
nia symptoms. To assess the clinical utility of melatonin for DSWPD, the observed effect sizes
Table 3. Subjective and objective sleep parameters at baseline and during all nights of the 28-d treatment period.
Baseline All nights Difference between treatment
groups’ change from baseline to
treatment
Placebo Melatonin Placebo Melatonin β (95% CI) P
Actigraphy
No.: participants; nights 55; 373 56; 378 51; 1,404 55; 1,518
No. nights per patient 6.78 ± 0.53 6.75 ± 0.55 27.53 ± 3.36 27.60 ± 2.97 0.10 (−1.13 to 1.33) 0.869
Bedtime (hh:mm): Mean ± SD 00:58 ± 01:49 01:11 ± 1:52 23:42 ± 1:41 23:38 ± 1:36 −0:20 (−0:50 to 0:11) 0.210
Sleep onset time (hh:mm)a: Mean ± SD 01:20 ± 01:49 01:32 ± 1:54 00:17 ± 1:44 00:03 ± 1:37b −0:29 (−0:54 to −0:04) 0.023
Sleep offset time (hh:mm): Mean ± SD 08:58 ± 1:57 08:56 ± 2:07 08:25 ± 1:51 08:08 ± 1:50 −0:17 (−0:40, 0:06) 0.144
Rise time (hh:mm): Mean ± SD 09:13 ± 1:56 09:09 ± 2:06 08:43 ± 1:49 08:25 ± 1:47 −0:18 (−0:41, 0:05) 0.111
TIB (h): Mean ± SD 8.24 ± 1.75 7.98 ± 1.81 9.00 ± 1.56 8.77 ± 1.55 0.00 (−0.36, 0.36) 0.995
TST (h): Mean ± SD 6.80 ± 1.51 6.62 ± 1.65 7.17 ± 1.45 7.24 ± 1.39 0.22 (−0.08, 0.52) 0.157
SOL (min): Mean ± SD 20.71 ± 26.21 21.14 ± 27.33 33.47 ± 37.05 24.90 ± 30.51b −9.68 (−16.69 to −2.67) 0.007
Median (IQR) 14 (2–27) 12 (3–29) 23 (8–46) 17 (6–34)
SE (%): Mean ± SD 82.78 ± 7.17 83.13 ± 8.21 79.73 ± 9.62 82.70 ± 8.43b 2.72 (0.59–4.86) 0.013
Median (IQR) 83.74 (78.26–88.06) 84.30 (79.07–89.22) 81.44 (75.63–86.09) 84.31 (78.97–88.54)
SE tertile 1 (%)
a
: Mean ± SD 83.78 ± 9.50 83.19 ± 12.47 79.32 ± 12.35 82.87 ± 10.36b 4.37 (1.91–6.83) 0.001
Median (IQR) 85.26 (78.95–90.65) 86.25 (77.74–91.79) 81.97 (74.29–87.73) 85.01 (78.14–90.27)
SE tertile 2 (%): Mean ± SD 89.57 ± 5.92 90.11 ± 6.15 88.19 ± 7.76 89.84 ± 8.11 0.98 (−0.33 to 2.30) 0.144
Median (IQR) 90.45 (86.82–93.57) 91,21 (87.74–94.17) 89.98 (85.96–92.75) 91.78 (87.85–94.48)
SE tertile 3 (%): Mean ± SD 85.03 ± 8.30 85.98 ± 7.67 84.47 ± 8.39 85.79 ± 8.50 0.11 (−1.37 to 1.60) 0.883
Median (IQR) 86.84 (80.56–90.71) 87.57 (82.62–91.48) 85.96 (80.59–90.30) 87.50 (82.17–91.55)
WASO (min): Mean ± SD 49.81 ± 25.84 45.44 ± 26.38 57.82 ± 29.96 50.31 ± 30.13 −3.13 (−8.88 to 2.61) 0.285
Median (IQR) 47 (31–63) 39.5 (27–56) 52 (38–70) 43 (31–61)
Sleep Diary
N: participants; nights 58; 394 58; 395 51; 1,404 55; 1,518
No. nights: Mean ± SD 6.79 ± 0.49 6.81 ± 0.51 27.53 ± 3.36 27.60 ± 2.97 0.05 (−1.18 to 1.28) 0.936
Bedtime (hh:mm): Mean ± SD 00:46 ± 1:44 01:01 ± 1:43 23:28± 1:41 23:25 ± 1:37 −0:20 (−0:44 to 0:04) 0.100
Sleep onset time (hh:mm): Mean ± SD 01:28 1:43 01:42 ± 1:44 00:20± 1:41 00:03 ± 1:40b −0:34 (−0:56 to −0:12) 0.002
Sleep offset time (hh:mm): Mean ± SD 09:01 ± 1:57 09:09 ± 2:06 08:41 ± 1:50 08:17 ± 1:51b −0:35 (−1:00 to −0:11) 0.005
ΤIΒ (h): Mean ± SD 8.25 ± 1.84 8.13 ± 1.76 9.21 ± 1.72 8.84 ± 1.84 −0.28 (−0.67 to 0.11) 0.164
ΤSΤ (h): Mean ± SD 7.22 ± 1.87 7.08 ± 1.91 7.93 ± 1.79 7.89 ± 1.96 0.08 (−0.33 to 0.49) 0.708
SOL (min): Mean ± SD 42.32 ± 45.98 41.47 ± 46.40 54.62 ± 56.76 38.68 ± 51.09b −15.45 (−26.22 to −4.68) 0.005
Median (IQR) 30 (15–60) 30 (15–50) 30 (20–65) 25 (15–45)
SE (%): Mean ± SD 87.41 ± 11.32 87.21 ± 14.17 86.16 ± 12.84 88.69 ± 14.11 2.78 (−0.64 to 6.21) 0.111
Median (IQR) 90.82 (82.73–95.65) 92.31 (83.33–95.97) 90.20 (81.58–94.85) 93.40 (86.21–96.43)
WASO (min): Mean ± SD 19.60 ± 28.14 21.51 ± 39.40 23.46 ± 40.80 19.60 ± 36.85 −5.28 (−14.42 to 3.85) 0.257
Median (IQR) 10 (0–30) 5 (0–30) 10 (0–30) 5 (0–20)
Median (IQR) presented for variables with skewed distribution.
aUnderlined variable indicates primary outcome.
bBolded results indicate statistically significant parameters.
Abbreviations: CI, confidence interval; IQR, interquartile range; SD, standard deviation; SE, sleep efficiency; SOL, sleep onset latency; TIB, time in bed; TST, total sleep
time; WASO, wake after sleep onset.
https://doi.org/10.1371/journal.pmed.1002587.t003
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should be compared to other treatments for DSWPD, ideally. Unfortunately, to our knowl-
edge, such studies are lacking. The effects reported for subjective SOL are comparable to those
of first-line therapies for insomnia, including cognitive behavioural therapy for insomnia [41]
and Z-class hypnotic agents [42]. The reduction in subjective insomnia severity is greater than
reported with Suvorexant for treatment of primary insomnia [43]. Our findings of reduced
functional impairments in work/school, social, and family life extend previous reports of
improvements in school performance in adolescents [44] and quality of life in adults [45] fol-
lowing melatonin treatment. After only 1 wk of treatment with melatonin, patient-reported
sleep-related impairment was significantly improved relative to placebo. The 4-point reduction
in PROMIS sleep-related impairment is comparable to the 5-point larger reduction reported
for cognitive behavioural therapy for insomnia modified for bipolar disorder compared to
psychoeducation [46] as well as the 4-point difference reported between individuals with a
recent mild traumatic brain injury and matched controls [47]. We suggest that these improve-
ments in daytime functional measures were secondary to the observed improvements in sleep
quality.
Fig 3. Raster plot of sleep-wake and work patterns for a representative DSWPD patient at baseline and during treatment with 0.5 mg melatonin.
Black bars: sleep with open bar illustrating sleep onset time; triangles: time of melatonin administration; dashed line: DBT; open bars: work. On nights
prior to daytime commitments on at least 5 nights per week, medication was taken 1 h before DBT identified prior to the study. DBT, desired bedtime;
DSWPD, Delayed Sleep-Wake Phase Disorder.
https://doi.org/10.1371/journal.pmed.1002587.g003
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Table 4. Improvements in standardised measures of subjective sleep quality, sleep-related impairment and daytime dysfunction at baseline and post-treatment for
the melatonin and placebo treatment groups.










































Absent (0–7) 8 (13.8) 9 (16.4) 0.713 13 (27.7) 27 (56.3)
Subthreshold
(8–14)
30 (51.7) 24 (43.6) 22 (46.8) 17 (35.4)
Moderate (15–
21) / Severe (22–
28)
20 (34.5) 22 (40.0) 12 (25.5) 4 (8.4)
PSQI
(mean ± SD)
















Normal (0–5) 12 (20.7) 10 (17.9) 0.814 15 (31.9) 21 (43.8)
Poor Sleep
(>5)
46 (79.3) 46 (82.1) 32 (68.1) 27 (56.3)






















9 (15.5) 9 (15.5) 3 (6.4) 3 (6.3)

























PGI-C, n (%)b 1.65 (0.76–
3.62)
0.239
No change to a
little better (1–3)
27 (55.1) 23 (42.6)
Somewhat
better to a great
deal better (4–7)
22 (44.9) 31 (57.4)
aFor the melatonin group at baseline; ISI n = 51; PSQI n = 52; SDS n = 52; absenteeism n = 51; presenteeism n = 51.
bFor PGI-C at post-treatment: placebo n = 49; melatonin n = 54.
cDifferences presented for categorical analyses for ISI, PSQI, ESS, and PGI-C are odds ratios.
Abbreviations: ESS, Epworth Sleepiness Scale; ISI, Insomnia Severity Index; PGI-C, Patients’ Global Impression of Change Scale; PSQI, Pittsburgh Sleep Quality Index;
SDS, Sheehan Disability Scale.
https://doi.org/10.1371/journal.pmed.1002587.t004
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Melatonin treatment advanced the timing of DLMO by 36 min more than with placebo
(0.73 versus 0.24 h), although this difference was not significant. There are several possible rea-
sons for this lack of difference in circadian phase shifting. Melatonin was scheduled to be
taken 1 h prior to DBT to facilitate sleep onset primarily through the direct, sleep-promoting
effects of the hormone [16] during the wake maintenance zone, when sleep propensity is low
[2,48]. In contrast, most previous trials of melatonin for DSWPD have focussed on the circa-
dian phase shifting properties of melatonin, which require that treatment be administered
several hours before the timing of habitual sleep or endogenous melatonin onset [13,14].
Although melatonin was administered on average 1.4 h before DLMO—which may be
expected to induce a modest phase advance [33,49]—because assessment of circadian phase
shifting was performed in only a subset of patients, the study may have been underpowered
to detect significant differences. Second, by instructing patients to attempt sleep at their DBT
(which may be the required bedtime for some individuals), the light-dark cycle was phase
advanced, resulting in an advance in the timing of the circadian pacemaker in both groups
[50]. Finally, our pragmatic treatment protocol required patients to take melatonin and sleep
at their DBT—which is typically earlier than the habitual bedtime—on at least 5 nights per
week, to accommodate work or school activities. On nights when patients did not sleep at their
DBT or take melatonin, the circadian pacemaker may have reverted to a delayed pattern, thus
counteracting the previous melatonin-induced phase advances. As an indirect consequence of
a protocol that allows patients to choose their own sleep-wake schedule, social jetlag (i.e., the
Table 5. Clinician-rated measures of sleep-related impairment from the CGI scale for treatment groups at baseline and post treatment.
Baseline Post-treatment Pa
Placebo (n = 58) Melatonin (n = 58) Placebo (n = 50) Melatonin (n = 54)
Severity, no. (%)
Normal to mildly ill (1–3) 19 (38.0) 19 (35.3) 25 (50.0) 34 (62.2) 0.365
Moderately ill (4) 22 (44.0) 29 (53.7) 22 (44.0) 17 (31.5)
Markedly ill to amongst the most extreme (5–7) 9 (18.0) 6 (11.2) 3 (6.0) 3 (5.6)
Global improvement, no. (%)b
Very much to much improved (1–2) 12 (24.0) 28 (52.8) 0.011
Minimally improved to minimally worse (3–5) 37 (74.0) 24 (45.3)
Much worse to very much worse (6–7) 1 (2.0) 1 (1.9)
Efficacy index 8.60 ± 4.32 6.87 ± 4.35 0.045
aChi-squared comparison between groups post treatment.
bGlobal Improvement melatonin group n = 53.
Abbreviation: CGI, Clinical Global Impression.
https://doi.org/10.1371/journal.pmed.1002587.t005
Table 6. Categorisation of adverse events reported in the placebo and melatonin treatment groups.
Category of symptoms Report frequency for each treatment group
Light-headedness n = 2 melatonin
n = 2 placebo
Daytime sleepiness n = 2 melatonin
n = 1 placebo
Decreased libido n = 2 melatonin
Headache n = 1 melatonin
Vivid dreams and/or nightmares n = 1 melatonin
n = 4 placebo
https://doi.org/10.1371/journal.pmed.1002587.t006
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difference in timing between treatment and nontreatment nights) could be increased, which
may have health implications [51]. We did not find a significant difference in the degree of
social jetlag between the melatonin and placebo groups.
Current melatonin treatment protocols for DSWPD vary in patient diagnostic and selection
criteria as well as in the dose, formulation, and timing of melatonin, and they may result in
low compliance, thus limiting translation into clinical practice. We improved on previous aca-
demic-led trials by selecting patients who have an endogenous circadian basis to their symp-
toms [52]. Furthermore, we have developed a pragmatic treatment protocol that allows
patients to improve sleep initiation when needed to accommodate daytime commitments the
following morning and found a high rate of compliance. This approach of allowing patients to
optimise treatment administration to align with clinical and lifestyle needs is highly novel and,
to our knowledge, has not been previously reported in the literature. The behavioural interven-
tion of attempting sleep at the earlier DBT facilitated earlier timing of sleep onset, as reflected
by the significant improvements in sleep outcomes in the placebo group (Tables 2 and 4).
These findings demonstrate that behavioural approaches for managing DSWPD appear to be
highly effective, potentially through altered light-dark cues. The improvements in sleep pro-
duced by the behavioural intervention were, however, considerably enhanced by melatonin
administration. This is important information for clinicians seeking an evidence-based thera-
peutic approach for DSWPD. We used a lower dose formulation than those typically used pre-
viously (3–5 mg) [10–12,14,44,53]. Our results demonstrate that large doses of melatonin are
not required for improvements in sleep initiation and daytime functioning in DSWPD
patients, noting, however, that a dose-response relationship has previously been reported [36].
Treatment of a circadian disorder with melatonin would be preferable to a traditional hyp-
notic given that melatonin both facilitates sleep and shifts the timing of the circadian pace-
maker [16]. There is a lack of evidence of the value of hypnosedatives in the treatment of
phenotyped DSWPD and a large body of literature on the adverse effects of such medications.
In addition to the properties of benzodiazepines as a muscle relaxant, the use of this class of
drugs is often associated with residual sleepiness the following morning, cognitive impair-
ments including memory, and issues of dependence and withdrawal [54]. The overdose death
rate with benzodiazepine use has increased from 0.58 to 3.07 per 100,000 adults [55]. A poten-
tially important clinical application for melatonin is in its use to facilitate discontinuation of
benzodiazepines [56].
Limitations of the study should be considered. The original sample size was not reached
due to slower-than-anticipated recruitment and financial constraints. Statistical significance
was still achieved in the main outcomes, probably because we only included patients with
delayed circadian phase relative to DBT, melatonin treatment was timed before DLMO, and
we continued treatment for 4 wk, compared to the variable protocols used in the studies that
informed our original sample size estimate [11,57–59]. The implications of smaller sample size
should be considered, including internal and external validity of the findings. Testing of effi-
cacy and safety were limited to a 4-wk interval. We did not assess clinical benefits or safety of
melatonin with long-term treatment, nor did we do a follow-up assessment after treatment
was discontinued. Furthermore, it remains unknown whether the same treatment regime
would benefit all patients who meet current (ICSD symptom-based) diagnostic criteria for
DSWPD but do not undergo further classification based on circadian phase. In our study,
patients were diagnosed via clinical interview based on ICSD-2 criteria. An updated version of
the ICSD incorporating recommendations to consider objective assessments, including circa-
dian phase, is now available.
Patients experiencing DSWPD symptoms without a circadian delay are not likely to be
sleeping in their wake maintenance zone, and therefore the soporific effects of melatonin may
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be diminished. One-third of patients diagnosed with DSWPD in the current study did not
present circadian misalignment between DLMO and DBT. It is important to include circadian
phase assessment in the diagnosis and management of DSWPD. It should also be noted that
some individuals with delayed sleep due to non-circadian reasons could ultimately experience
delayed circadian timing due to delayed light-dark exposure on an ongoing basis. This has
implications for the growing prevalence of DSWPD and for treatment protocols such as cogni-
tive behavioural therapy for insomnia, which includes the practice of stimulus control, in
which patients can be encouraged to rise from bed in the evening if they are unable to fall
asleep, subsequently exposing themselves to phase-delaying light.
Although the formulation of melatonin used in this trial was certified for its purity and
quality, access to pharmaceutical-grade melatonin is variable across different countries. In
numerous countries, a compounding pharmacist must deliver an accurate dosage of melato-
nin. In countries such as the United States in which melatonin is not regulated, however, issues
of quality, dose, and preparation are likely to be a concern for clinicians. These practical limita-
tions, together with the lack of access to circadian phase assessments, present some barriers to
translation of the current findings. This trial does, however, support the clinical utility of circa-
dian diagnostic and treatment approaches in order to bring clinical practice in line with scien-
tific discoveries in the field.
We showed that short-term, low-dose melatonin administration in a pragmatic treatment
protocol with behavioural sleep-wake scheduling is an efficacious and safe treatment for
DSWPD patients with confirmed circadian misalignment, resulting in improvements in objec-
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